恩替卡韦治疗活动性乙型肝炎肝硬化42例临床观察

目的：探讨恩替卡韦治疗活动性乙型肝炎肝硬化的临床效果。方法：选择本院2007年8月～2009年8月活动性乙型肝炎肝硬化患者82例,将以上患者随机分为两组,观察组和对照组。对照组患者采用常规治疗,观察组在常规治疗基础上给予恩替卡韦。两组患者疗程为48周。测定两组患者治疗前和治疗后生化指标;测定两组患者治疗后HBV-DNA阴转率、HBeAg血清转换率等。结果：观察组治疗后TBIL、ALT、ALB、Child-pugh评分与对照组治疗后比较,差异有统计学意义（P〈0.05）;观察组治疗后HBV-DNA转阴率和HbeAg血清转换率分别与对照组比较,差异有统计学意义（P〈0.05）。结论：恩替卡韦能够快速抑制乙肝病毒复制,改善患者临床症状和生化指标,临床效果显著,值得借鉴。

Clinical evaluation of entecavir on 42 cases with liver cirrhosis of reactive type B hepatitis

Objective： To explore the clinical observation of entecavir on liver cirrhosis of reactive type B hepatitis. Methods： 82 cases with liver cirrhosis of reactive type B hepatitis were selected from February 2007 to August 2009, and divided into control group and observation group. Routine treatment was used to control group, and entecavir was given to observation group on the base of routine treatment, the course was 48 weeks, the biochemical index was detected in two groups before and after treatment, the rate of HBeAg turn to negative and HBeAg seroconversion was detected after treatment. Results： TBIL,ALT,ALB ,the scores of Child-pughin observation group after treatment compared with those in control group respectively, there was statistical difference （P〈0.05）; the rate of HBeAg turn to negative and HBeAg seroeonversion in observation group compared after treatment with those in control, there was statistical difference （P〈0.05）. Conclusion： Ntecavir can inhabit the copy of type B hepatitis, and＇improve the clinical symptoms and the biochemical index, the clinical efficacy is significant, and the therapy should be the reference for doctors.